



Ramona Bürki

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Ramona Bürki

T +41 71 494 1288

Ramona.Buerki@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Profile Function

study nurse

Publications (0)

No results found.

Projects (8)

A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors

Clinical Studies - Aug 27, 2024 - Dec 31, 2099

Ongoing

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)

Clinical Studies - Apr 18, 2024 - Dec 31, 2099

Ongoing

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Clinical Studies - Oct 30, 2023 - Dec 31, 2099

Ongoing

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Mono-therapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)

Clinical Studies - Mar 2, 2023 - Oct 2, 2023

Completed

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Clinical Studies - Feb 7, 2023 - Dec 31, 2099

Ongoing

CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS

Clinical Studies - Sep 2, 2022 - Dec 31, 2099

Ongoing

INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA

Clinical Studies - Apr 20, 2022 - Dec 31, 2025

Ongoing

INCMOR0208-301

Clinical Studies - Apr 20, 2021 - Dec 31, 2099

Ongoing

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch